Quipazine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jytdog (talk | contribs) at 16:53, 15 February 2016 (→‎Synthesis: remove content added by sock of banned user Nuklear). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Quipazine
Clinical data
ATC code
  • none
Identifiers
  • 2-piperazin-1-ylquinoline
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.164.885 Edit this at Wikidata
Chemical and physical data
FormulaC13H15N3
Molar mass213.278 g/mol g·mol−1
3D model (JSmol)
  • C1CN(CCN1)C2=NC3=CC=CC=C3C=C2
  • InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2 ☒N
  • Key:XRXDAJYKGWNHTQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Quipazine is a piperazine drug used in scientific research. It is a moderately selective serotonin receptor receptor agonist, binding to a range of different serotonin receptors, but particularly to the 5-HT2A[1] and 5-HT3.[2]

See also

References

  1. ^ Smith, R. L.; Barrett, R. J.; Sanders-Bush, E (1995). "Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor". The Journal of pharmacology and experimental therapeutics. 275 (2): 1050–7. PMID 7473132.
  2. ^ Cappelli, A; Anzini, M; Vomero, S; Mennuni, L; Makovec, F; Doucet, E; Hamon, M; Bruni, G; Romeo, M. R.; Menziani, M. C.; De Benedetti, P. G.; Langer, T (1998). "Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives". Journal of Medicinal Chemistry. 41 (5): 728–41. doi:10.1021/jm970645i. PMID 9513601.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Quipazine&oldid=705120328"